Skip to main content

Table 6 Clinical HHT-related features of the 9 patients with hereditary hemorrhagic telangiectasia (HHT) with ascertained SarsCov-2 infection

From: Characterization of epidemiological distribution and outcome of COVID-19 in patients with hereditary hemorrhagic telangiectasia: a nationwide retrospective multi-centre study during first wave in Italy

Clinical, HHT-related (n = 9a)
Epistaxis, n (%) 9 (100)
Visceral AVMs, n (%) 2 (22.2)
Epistaxis Worsening, n (%) 3 (33.3)
Epistaxis Unchanged, n (%) 6 (66.7)
Epistaxis Improvement, n (%) 0
Increased bleeding from oral telangiectases, n (%) 0
Chronic Anemia
Hb deficit level (n = 6a)  
 Mild, n 5
 Intermediate, n 1
 Severe, n 0
 Very Severe, n 0
Iron replacement therapy (n = 8a)  
 Oral Supplementation, n 3
 IV Injection, n 2
 Blood Transfusion, n 0
  1. AVMs = Arterio-Venous Malformations; Hb level deficit: Mild (Hb > 12 gr/dl), Intermediate (10–12 gr/dl), Severe 7–10 gr/dl), Very Severe (< 7 gr/dl); aNumber of respondents for each variable